In vitro metabolism of α7 neuronal nicotinic receptor agonist AZD0328 and enzyme identification for its N-oxide metabolite

Xenobiotica

Volumn 41, Issue 3, 2011, Pages 232-242

  Zhou, Diansong ^a   Zhang, Minli ^a   Ye, Xiaomei ^a   Gu, Chungang ^a   Piser, Timothy M ^a   Lanoue, Bernard A ^a   Schock, Sara A ^a   Cheng, Yi Fang ^b   Grimm, Scott W ^a  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

cytochrome P450; hepatocyte; human liver S9 fraction; Metabolism; N glucuronidation; N methylation

Indexed keywords

ALPHA 7 NEURONAL NICOTINIC RECEPTOR AGONIST; AZD 0328; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 INHIBITOR; ENZYME; FMO1 ENZYME; FMO3 ENZYME; FURAFYLLINE; FUROPYRIDINE; MONTELUKAST; N 3 BENZYLNIRVANOL; NICOTINIC AGENT; OCTANE; PYRIDINE DERIVATIVE; SULFAPHENAZOLE; THIAMAZOLE; TICLOPIDINE; TRANYLCYPROMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DRUG CLEARANCE; DRUG IDENTIFICATION; DRUG INHIBITION; DRUG METABOLISM; ENZYME ANALYSIS; FEMALE; GENETIC POLYMORPHISM; GUINEA PIG; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROXYLATION; IN VITRO STUDY; LIVER MICROSOME; MALE; NONHUMAN; OXIDATION; RAT;

ANIMALS; CYCLIC N-OXIDES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; CYTOSOL; DOGS; FEMALE; FURANS; GUINEA PIGS; HEPATOCYTES; HUMANS; MALE; NICOTINIC AGONISTS; OXYGENASES; QUINUCLIDINES; RATS; RATS, SPRAGUE-DAWLEY;

CANIS FAMILIARIS; CAVIA; RATTUS;

EID: 79951841206     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2010.536855     Document Type: Article

References (27)

1. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA; Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Research (CDER). (2003). The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815-832. (Pubitemid 36759050)
2. Bjugstad KB, Mahnir VM, Kem WR, Socci DJ, Arendash GW (1996) Long-term treatment with GTS-21 or nicotine enhances water maze performance in aged rats without affecting the density of nicotinic receptor subtypes in neocortex. Drug Dev Res 39:19-28. (Pubitemid 27076203)
3. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. (2007). Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3:186-191. (Pubitemid 46825511)
4. Burghaus L, Schütz U, Krempel U, de Vos RA, Jansen Steur EN, Wevers A, Lindstrom J, Schröder H. (2000). Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. Brain Res Mol Brain Res 76:385-388. (Pubitemid 30179776)
5. Cashman JR, Zhang J. (2006). Human flavin-containing monooxygenases. Annu Rev Pharmacol Toxicol 46:65-100. (Pubitemid 43271184)
6. Damani LA, Shaker MS, Crooks PA, Godin CS, Nwosu C. (1986). N-methylation and quaternization of pyridine in vitro by rabbit lung, liver and kidney N-methyltransferases: an S-adenosyl-Lmethionine- dependent reaction. Xenobiotica 16:645-650. (Pubitemid 16100795)
7. de Graaf C, Vermeulen NP, Feenstra KA. (2005). Cytochrome p450 in silico: an integrative modeling approach. J Med Chem 48:2725-2755. (Pubitemid 40548088)
8. Guan ZZ, Zhang X, Ravid R, Nordberg A. (2000). Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J Neurochem 74:237-243. (Pubitemid 30012774)
9. Hawes EM. (1998). N+-glucuronidation, a common pathway in human metabolism of drugs with a tertiary amine group. Drug Metab Dispos 26:830-837. (Pubitemid 28452048)
10. Kitagawa H, Takenouchi T, Azuma R, Wesnes KA, Kramer WG, Clody DE, Burnett AL. (2003). Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology 28:542-551.
11. Ko JW, Desta Z, Soukhova NV, Tracy T, Flockhart DA. (2000). In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. Br J Clin Pharmacol 49:343-351. (Pubitemid 30195277)
12. Lin JH. (1998). Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab Dispos 26:1202-1212. (Pubitemid 29028641)
13. Lin JH, Wong BK. (2002). Complexities of glucuronidation affecting in vitro in vivo extrapolation. Curr Drug Metab 3:623-646. (Pubitemid 35331663)
14. Levin ED, Bettegowda C, Blosser J, Gordon J. (1999). AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats. Behav Pharmacol 10:675-680. (Pubitemid 30026062)
15. Levin ED, McClernon FJ, Rezvani AH. (2006). Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl) 184:523-539. (Pubitemid 43255869)
16. Obach RS. (1999). Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
17. Olesen OV, Linnet K. (1999). Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology 59:298-309.
18. Pacifici GM, Franchi M, Bencini C, Repetti F, Di Lascio N, Muraro GB. (1988). Tissue distribution of drug-metabolizing enzymes in humans. Xenobiotica 18:849-856.
19. Parsons RB, Smith ML, Williams AC, Waring RH, Ramsden DB. (2002). Expression of nicotinamide N-methyltransferase (E.C. 2.1.1.1) in the Parkinsonian brain. J Neuropathol Exp Neurol 61:111-124. (Pubitemid 34127095)
20. Rezvani AH, Kholdebarin E, Brucato FH, Callahan PM, Lowe DA, Levin ED(2009) Effect of R3487/MEM3454, a novel nicotinic alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats. Prog Neuropsychopharmacol Biol Psychiatry 33: 269-275.
21. Rini J, Szumlanski C, Guerciolini R, Weinshilboum RM. (1990). Human liver nicotinamide N-methyltransferase: ion-pairing radiochemical assay, biochemical properties and individual variation. Clin Chim Acta 186:359-374. (Pubitemid 20040320)
22. Shaffer CL, Gunduz M, Scialis RJ, Fang AF. (2007). Metabolism and disposition of a selective alpha(7) nicotinic acetylcholine receptor agonist in humans. Drug Metab Dispos 35:1188-1195. (Pubitemid 46956441)
23. Sydserff S, Sutton EJ, Song D, Quirk MC, Maciag C, Li C, Jonak G, Gurley D, Gordon JC, Christian EP, Doherty JJ, Hudzik T, Johnson E, Mrzljak L, Piser T, Smagin GN, Wang Y, Widzowski D, Smith JS. (2009). Selective alpha7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes. Biochem Pharmacol 78:880-888.
24. Tarditi A, Caricasole A, Terstappen G. (2009). Therapeutic targets for Alzheimer's disease. Expert Opin Ther Targets 13:551-567.
25. Taly A, Corringer PJ, Guedin D, Lestage P, Changeux JP. (2009). Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov 8:733-750.
26. Thomsen MS, Hansen HH, Timmerman DB, Mikkelsen JD. (2010). Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Curr Pharm Des 16:323-343.
27. Zhou SF, Liu JP, Lai XS. (2009). Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development. Curr Med Chem 16:2661-2805.